Skip to content

US · ALZN · BIOTECHNOLOGY

Alzamend Neuro Inc (ALZN) intrinsic value and stock valuation

$0.78as of 2026-11-21 · Mkt cap 5.44M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alzamend Neuro Inc DCF and intrinsic value

InvestorsCraft values ALZN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALZN’s statements →

Alzamend Neuro Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Atlanta, GA 30326 alzamend.com

How the business is doing

Fiscal 2016–2026, USD

Revenue
$0.00
20162026
Net income
-$-8.77M
20162026
Free cash flow
-$-8.07M
20162026
Total equity
$730K-18.3% 5y CAGRd
20162026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2026, USD
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-8.77M-$-4.5M-$-9.94M-$-14.87M-$-12.32M
Net income-$-8.77M-$-4.51M-$-9.95M-$-14.88M-$-12.36M
EPSd-$-2.63M-$-10.02M-$-124.37M-$-212.57M-$-176.57M
Operating cash flow-$-8.07M-$-6.57M-$-8.27M-$-8.92M-$-6.61M
Capital expenditure$0.00-$-300K-$-150K$0.00-$-110K
Free cash flow-$-8.07M-$-6.87M-$-8.42M-$-8.92M-$-6.72M
Total assets$2.08M$4.6M$630K$5.92M$14.5M
Total debt$0.00$0.00$300K$0.00$0.00
Net debt-$-710K-$-3.95M-$-80K-$-5.14M-$-14.06M
Total equity$730K$3.97M-$-2.59M$3.05M$13.4M
Cash and short-term investments$710K$3.95M$380K$5.14M$14.1M
Income statement
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$3.63M$1.41M$6.46M$7.45M$5.2M
Selling, general and administrative expenses$5.14M$3.08M$3.48M$7.42M$7.12M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$8.77M$4.5M$9.94M$14.9M$12.3M
Cost and expenses$8.77M$4.5M$9.94M$14.9M$12.3M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense-$-10K$20K$10K$10K$50K
Depreciation and amortization$0.00$50K$50K$20K$0.00
Ebitda-$-8.77M-$-4.45M-$-9.89M-$-14.85M-$-12.31M
Operating income-$-8.77M-$-4.5M-$-9.94M-$-14.87M-$-12.32M
Total other income/expenses, net-$-10K-$-20K-$-10K-$-10K-$-40K
Income before tax-$-8.77M-$-4.51M-$-9.95M-$-14.88M-$-12.36M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-8.77M-$-4.51M-$-9.95M-$-14.88M-$-12.36M
Weighted average shares outstanding$3.34M$400K$70K$70K$70K
Weighted average diluted shares outstanding$3.34M$450K$80K$70K$70K
Balance sheet
20262025202420232022
Cash and short-term investments$710K$3.95M$380K$5.14M$14.1M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$1.76M$4.18M$460K$5.84M$14.4M
Property, plant and equipment, net$310K$430K$180K$80K$100K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$310K$430K$180K$80K$100K
Total assets$2.08M$4.6M$630K$5.92M$14.5M
Accounts payable$1.35M$630K$2.93M$2.87M$1.16M
Short-term debt$0.00$0.00$300K$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.35M$630K$3.23M$2.87M$1.16M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$1.35M$630K$3.23M$2.87M$1.16M
Common stock$0.00$0.00$0.00$10K$10K
Retained earnings-$-67.31M-$-58.54M-$-54.02M-$-44.07M-$-29.19M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-14.88M-$-14.88M
Total equity$730K$3.97M-$-2.59M$3.05M$13.4M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$300K$0.00$0.00
Net debt-$-710K-$-3.95M-$-80K-$-5.14M-$-14.06M
Cash flow statement
20262025202420232022
Net income-$-8.77M-$-4.51M-$-9.95M-$-14.88M-$-12.36M
Depreciation and amortization$110K$50K$50K$20K$0.00
Stock-based compensation$710K$330K$960K$3.58M$4.41M
Change in working capital-$-110K-$-2.44M$670K$2.35M$1.33M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$710K$0.00$0.00$0.00$690K
Net cash provided by operating activities-$-8.07M-$-6.57M-$-8.27M-$-8.92M-$-6.61M
Investments in property, plant and equipment$0.00-$-300K-$-150K$0.00-$-110K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-300K-$-150K$0.00-$-110K
Common stock issued$790K$2.7M$1.25M$0.00$18.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.83M$10.4M$3.65M$0.00$18.9M
Net change in cash-$-3.24M$3.57M-$-4.76M-$-8.92M$12.1M
Cash at end of period$710K$3.95M$380K$5.14M$14.1M
Operating cash flow-$-8.07M-$-6.57M-$-8.27M-$-8.92M-$-6.61M
Capital expenditure$0.00-$-300K-$-150K$0.00-$-110K
Free cash flow-$-8.07M-$-6.87M-$-8.42M-$-8.92M-$-6.72M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alzamend Neuro Inc

        Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

        CEO
        Stephan Jackman
        Employees
        7
        Beta
        0.19

        Explore

        Frequently asked questions

        What is the intrinsic value of Alzamend Neuro Inc (ALZN)?

        InvestorsCraft does not currently publish an intrinsic value for ALZN. How the IC value is calculated.

        Is ALZN undervalued?

        InvestorsCraft does not publish an undervaluation signal for ALZN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.